Inhalon Biopharma is a clinical-stage biotechnology company developing faster-acting, more effective, self-administered inhaled treatments to address the over $40B worldwide unmet need for patients suffering from acute respiratory infections (ARIs), such as respiratory syncytial virus (RSV), influenza, hMPV and SARS-CoV-2. Inhalon is using its patented drug delivery platform to revolutionize the treatment of viral respiratory infections. Inhalon’s breakthrough is a muco-trapping technology that directly binds to the virus and physically clears it from the airways. Virus trapping results in immediate reduction of viral load and prevents severe infection. Inhalon is the only company with broad issued patents covering inhaled treatment of ARIs with human monoclonal antibodies. Already, current partnerships with USAMRDC, NIH and Celltrion Healthcare have provided validation and funding to advance Inhalon’s proprietary platform. Inhalon’s technology is entirely novel and provides significant advantages to today’s anti-viral therapies, including: --Inhaled, nebulized antibodies that deliver an overwhelming dose directly to the site of infection without a delay in reaching Cmax. For most high-risk patients, this could mean prevention of hospitalization and lead to a faster recovery. --Direct, topical delivery that potentially increases the treatment window from beyond 48 hours (typical of oral medications) to 96 hours, a benefit for all patients. Utilizing the gold standard, large animal, lamb challenge model, Inhalon has demonstrated that its inhaled treatment significantly mitigated tissue damage from established viral infection and reduced virus titers by over 4 logs (to non-detectable levels). By Q4 of this year, Inhalon will be completing a landmark Phase 1b study that is expected to demonstrate superiority of inhaled vs. IV-administered antibodies. This follows Inhalon’s first Phase 1 study that demonstrated safety with inhaled administration.